Advertisement

Topics

Agendia, Inc. Company Profile

18:19 EDT 19th September 2018 | BioPortfolio

Agendia is a privately owned, leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their complex treatment decisions. Agendia’s breast cancer suite was developed using an unbiased gene selection by analyzing the complete human genome. This includes FDA-cleared MammaPrint as well as BluePrint, a molecular subtyping assay that provides deeper insight leading to more clinically actionable biology, and TargetPrint®, an ER/PR/HER2 expression assay. MammaPrint is the only breast cancer recurrence assay back by peer-reviewed, prospective outcome data. These tests can help physicians assess a patient’s individual risk for metastasis, which patients may benefit from chemo, hormonal, or combination therapy, and which patients may not require these treatments and can instead be treated with other, less arduous and less costly methods.


News Articles [10 Associated News Articles listed on BioPortfolio]

Agendia, Angsana Molecular enter marketing deal

A marketing deal was reached by Agendia and Angsana Molecular & Diagnostics Laboratory allowing Angsana to market Agendia's M -More- 

Late-stage round brings $35mm to Agendia

Agendia Inc. raised $35mm through a late-stage round from funds managed by Athyrium Capital Management. Agendia markets DNA microarray-based molecular diagnostics and will use some of the funds to sup...

US Oncology Research joins Agendia's FLEX big data initiative

(Weber Shandwick) Agendia, Inc., a world leader in precision oncology, announced today that US Oncology Research, one of the nation's largest research networks dedicated to bringing cutting-edge treat...

EU OKs Agendia's NGS MammaPrint BluePrint kit

Agendia's next-generation sequencing-based MammaPrint BluePrint kit, designed for breast cancer recurrence risk testing and m -More- 

A Personalized Genetic Test for Breast Cancer Arrives in Europe

Agendia will launch a next-generation sequencing test in the EU to determine the chances of metastasis in breast cancer patients.  Agendia, a US-Dutch biotech specializing in personalized medicine an...

Agendia’s MammaPrint® and BluePrint® Breast Cancer Tests Selected by Unicancer for French Patients

Irvine, CA, USA and Amsterdam, the Netherlands, May 15, 2018 / B3C newswire / -- Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announce that Unicancer, a ho...

Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

IRVINE, CA, AMSTERDAM, NETHERLANDS – 21 March 2018 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its next-generation seq...

Agendia Announces CE Mark for NGS-Based MammaPrint® BluePrint® Kit Enhancing Access to Personalized Treatment for Breast Cancer Patients in Europe

Irvine, CA, USA, Amsterdam, the Netherlands, March 21, 2018 / B3C newswire / --  Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, today announces that its...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [3 Associated Companies listed on BioPortfolio]

Agendia BV

Agendia, located in Amsterdam, The Netherlands, is a world leader in gene expression analysis-based diagnostics with three products on the market. The company focuses on the development and commer...

Agendia, Inc.

Agendia is a privately owned, leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products, which help support physicians with their compl...

Agendia B.V.

Agendia is at the forefront of the personalized medicine revolution, striving to bring more effective, individualized treatment within reach of patients. Building on a cutting edge genomics platform f...

More Information about "Agendia, Inc." on BioPortfolio

We have published hundreds of Agendia, Inc. news stories on BioPortfolio along with dozens of Agendia, Inc. Clinical Trials and PubMed Articles about Agendia, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Agendia, Inc. Companies in our database. You can also find out about relevant Agendia, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...


Corporate Database Quicklinks



Searches Linking to this Company Record